Zealand Pharma A/S (FRA:22Z)

Market Cap	3.71B -43.0%
Revenue (ttm)	1.23B +14,598.9%
Net Income	864.30M
EPS	12.08
Shares Out	n/a
PE Ratio	4.30
Forward PE	33.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	30
Open	50.74
Previous Close	51.50
Day's Range	50.74 - 50.74
52-Week Range	41.45 - 99.90
Beta	n/a
RSI	36.41
Earnings Date	Feb 19, 2026

About Zealand Pharma

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 440
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 22Z

Financial Performance

Financial numbers in DKK